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Abstract Expanded carrier screening (ECS), introduced in
2009, identifies carriers for dozens or hundreds of recessive
diseases. At the time of its introduction into clinical use, per-
spectives of the genetic counseling community regarding ECS
were unknown. We conducted a survey in early 2012 of GCs
and report the results here. They represent a snapshot of opin-
ions and usage at that time, providing a baseline for compar-
ison as the technology continues to evolve and as usage in-
creases. The survey assessed personal perspectives, opinions
on clinical implementation and clinical utilization of ECS. The
sample included 337 GCs of varying clinical fields, of whom
150 reported practicing in reproductive settings. Our findings
demonstrate that, at the time, GCs indicated general agree-
ment with ECS as a concept – for example, most GCs agreed
that carrier screening should address diseases outside of cur-
rent guidelines and also indicated personal interest in electing
ECS. There were also disagreements or concerns expressed
regarding appropriate pre- and post-test counseling (e.g., the
content and delivery mode of adequate informed consent) and
practical implementation (e.g., the amount of time available
for follow-up care). This was the first quantitative study of a
large number of GCs and it revealed initial overall support for
ECS among the GC profession. The authors plan to re-
administer a similar survey, which may reveal changes in
opinions and/or utilization over time. A follow up survey
would also allow further exploration of questions uncovered
by these data.
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Introduction
Expanded carrier screening (ECS) uses next-generation se-
quencing or microarray hybridization analysis to detect muta-
tions in many genes associated with recessive genetic dis-
eases. The same objective remains as that of standard single-
gene analysis protocols: identification of couples at risk for
transmitting genetic conditions in order to guide reproductive
decision-making in the prenatal or preconception period
(Edwards et al. 2015; Grody et al. 2013). Clinically introduced
in 2009, multiple laboratories now offer panels that vary in
diseases and mutations tested and other characteristics. The
general focus, however, tends toward diseases with pediatric
implications. By comparison, carrier screening has tradition-
ally focused on limited diseases of high prevalence, either in
certain ethnicities or universally, based on guidelines issued
by the American Congress of Obstetricians and Gynecologists
(ACOG) and American College of Medical Genetics and
Genomics (ACMG) (ACOG 2007, 2009, 2011; Gross et al.
2008; Prior 2008).
Carrier screening is voluntary in nature. Though individ-
uals may decide whether to undergo screening, the specific
testing options available to them are often dependent on the
provider’s practices, since a physician’s offering and prescrip-
tion are generally required. Given the lack of guidance on
whether and how to offer ECS, varying clinical practices can
be anticipated.
Genetic counselors (GC) are exposed to and may utilize
emerging genetic testing technologies more rapidly.
Therefore, their insights and preferences regarding expanded
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screening often influence other providers who offer carrier
screening. Limited data are available regarding GC attitudes,
beliefs and preferences regarding ECS. Cho et al. (2013) con-
ducted focus group interviews and identified themes of per-
ceived benefits and disadvantages of ECS. For example, their
participants expected that patient interest in ECS would be
high and acknowledged its financial value, but they also
expressed concern about the possibility of false reassurance
and specific construction of the disease panels. Forty genetics
professionals participated in their study, a sample which may
have included non-GCs. Therefore, the Cho et al. study rep-
resents a small subset of the total GC population (National
Society of Genetic Counselors 2012).
This study’s purpose was to conduct an extensive survey in
a large GC population on personal and professional attitudes




An anonymous, online survey assessing knowledge and atti-
tudes of GCs toward ECS was distributed to all 3,039 partic-
ipating members of the National Society of Genetic
Counselors (NSGC) via email from 2/2012 to 4/2012
(NSGC 2012). By consenting to participate, responders veri-
fied that they held a master’s degree in Genetic Counseling or
Human Genetics, or equivalent. The survey was anonymous
but participants could voluntarily enter a raffle for one of three
iPads (Apple Corporation, Cupertino, CA). We utilized an
online survey service, Wufoo (SurveyMonkey, Inc., Palo
Alto, CA). This study was approved by the Institutional
Review Board of the University of Medicine and Dentistry
of New Jersey, now Rutgers-Robert Wood Johnson Medical
School (New Brunswick, NJ).
Instrumentation
The investigator-created survey consisted of 65 questions
divided into 7 sections. Sections included were: criteria
for inclusion in an ECS panel (9 questions), GCs’ personal
feelings about ECS (9 questions), experience with ECS
tests (6 questions), role of genetic counseling for ECS (8
questions), criteria for offering ECS (19 questions), knowl-
edge assessment (7 questions) and demographics (7 ques-
tions). The majority of questions evaluated level of agree-
ment using a 5-point Likert scale. Since all survey ques-
tions were voluntary, a fluctuation in question-specific re-
sponse rate was possible.
Data Analysis
Frequencies were calculated for responses to each of the sur-
vey items. On some items, we also compared responses be-
tween participants working in reproductive genetics settings
and those working in others. We assessed statistical signifi-
cance by utilizing the pooled two sample z-test.
Results
Response Rate and Demographics
In total, 337 GCs completed the survey, resulting in an 11.1 %
response rate based on the 2012 NSGC membership of 3,039.
Forty-four percent (n=150) of the respondents indicated re-
productive genetics as their primary field of practice, meaning
either prenatal, infertility or ART/IVF, or PGD/preconception
settings were their primary practice types. In 2012, NSGC
reported approximately 900 GCs working in reproductive
fields (prenatal, infertility, ART/IVF, and PGD/preconception)
(NSGC 2012). Therefore, we estimated that we surveyed ap-
proximately 17% of reproductive GCs. Our study sample was
94 % female and 91 % Caucasian, consistent with the NSGC
membership demographics at the time (NSGC 2012). The
majority (61 %) were 25–34 years old. Geographically, the
highest representations came from Regions II (34 %),
consisting of states from New York to the Mid-Atlantic, and
IV (25 %), which encompasses the Midwest. Almost half of
respondents (48 %) had 1–4 years of genetic counseling ex-
perience, and 25% had 5–9 years of experience. Various work
settings were reported, including university medical center
(37 %), private hospital/medical facility (20 %), public
hospital/medical facility (17 %), commercial laboratory
(8 %), and physician private practice (7 %). Table 1 reports
complete demographic information.
Although we surveyed GCs from all fields in order to gain
broad perspectives and potentially observe differences, some
results below pertain only to those who indicated current prac-
tice in reproductive genetics (n=150). In general, where ques-
tions pertained to actual clinical practice, we report data only
from GCs that reported working in reproductive genetics
(RGCs). Where questions assess opinions or beliefs, we report
all pooled data. Though in general there were no differences
between GCs and RGCs, key areas of statistically significant
differences are described at the end of the Discussion.
Genetic Counselor Personal Perspectives
Personal perspectives were ascertained with the recognition
that what a GC may choose for him/herself may differ from
what is offered to patients in a clinical setting. Among all GCs
surveyed, most reported that they would personally pursue
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ECS and would rather be screened for a larger number of
conditions. A minority, 19 %, would opt out of ECS during
pregnancy and fewer (5 %) would opt out prior to conception
due to anxiety. The majority (80 %) agreed that if cost were
the same, they would prefer to be tested for a large number of
conditions – and 90 % would want to know if they were
carriers for conditions beyond the ACOG/ACMG guidelines.
When considering reproductive options for carrier couples,
92 % would personally opt for prenatal diagnosis (CVS or
amniocentesis) if the fetus were at risk for a recessive condi-
tion. Interestingly, fewer (78 %) would consider pre-
implantation genetic diagnosis to reduce their reproductive
risks. The majority disagreed with the statements that ECS
would lead to decreased funding for genetic disorders
(67 %) or decreased societal tolerance of disabilities (61 %).
Refer to Fig. 1 for comprehensive response data for this
section.
Clinical Availability and Implementation
We report reproductive GCs (RGCs) views on early clinical
availability of ECS and its implementation into clinical prac-
tice. Less than half (42 %) of RGCs responded that they were
very knowledgeable about ECS technology. However, 62 %
Table 1 Responder demographicsa
Reproductive GC n (%) Non-reproductive GC n (%)
Gender
male 6 (4.3 %) 14 (7.5 %)
female 133 (95.7 %) 174 (92.6 %)
Age
20–24 5 (3.7 %) 8 (4.4 %)
25–29 45 (33.1 %) 70 (38.0 %)
30–34 30 (22.1 %) 51 (27.7 %)
35–39 30 (22.1 %) 30 (16.3 %)
40–44 9 (6.6 %) 12 (6.5 %)
45–49 10 (7.3 %) 5 (2.7 %)
50–54 7 (5.2 %) 8 (4.4 %)
Ethnicity
American Indian or Alaskan Native 0 1 (0.5 %)
Asian 5 (3.6 %) 13 (6.6 %)
Black or African-American 2 (1.4 %) 1 (0.5 %)
Caucasian or white 133 (94.3 %) 184 (88.8 %)
Hispanic/Chicano/Latino 0 4 (2.0 %)
Native Hawaiian or Pacific Islander 0 2 (1.0 %)
other 1 (0.7 %) 1 (0.5 %)
NSGC region
Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces) 12 (8.5 %) 15 (8.0 %)
Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec) 45 (31.7 %) 66 (35.0 %)
Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN) 10 (7.0 %) 14 (7.4 %)
Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario) 32 (22.5 %) 51 (27.0 %)
Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask.) 21 (15.0 %) 18 (9.5 %)
Region 6 (AK, CA, HI, ID, NV, OR, WA, British Columbia) 22 (15.5 %) 25 (13.2 %)
Years in practice
1–4 64 (51.2 %) 88 (49.7 %)
5–9 25 (20.0 %) 54 (30.5 %)
10–14 26 (20.8 %) 31 (17.5 %)
15–19 10 (8.0 %) 4 (2.3 %)
20–25 0 0
>25 5 (4.0 %) 9 (5.1 %)
a : n=337 total GCs completed the survey by reaching its end. Individuals were not required to answer every question. Throughout the survey, and in this
table, responses may not sum to 337
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were comfortable explaining the genetic information ECS
would provide (Fig. 2). The majority did not offer ECS at all
(52 %) and (40 %) offered it to less than one-third of their
patients. Six RGCs were offering ECS to all of their patients,
but 92 % stated ECS would be routinely incorporated into
clinical genetics in the future. Some of the barriers to routine
implementation included concerns such as amount of time
spent counseling patients regarding ECS results (53 %) and
time needed to coordinate follow-up testing (59 %).
Two questions assessed the potential impact of perceived
socioeconomic status (SES) on the implementation of ECS in
clinical practice: I use my perception of the patient’s SES in
choosing which test options I offer; and I offer all of my pa-
tients identical carrier screening options, regardless of their
SES. We expected responses to these two questions to be
consistent. Consistency would be observed if responders
disagreed with the first statement and agreed with the second
– effectively, saying, BI do not use perceived SES in choosing
which tests to offer, therefore I do offer all of my patients
identical carrier screening options regardless of SES.^ RGCs
generally disagreed (85 %) with the first statement, but less
agreed with the second (74 %). While the discrepancy only
applies to a minority of respondents, it was statistically signif-
icant (p=0.03).
Perspectives on Panel Inclusion
Another survey goal was to assess views on diseases to be
included on an ECS panel. These data regard opinions on all
GCs surveyed. Of all respondents, 27 % agreed that ECS
should be limited to conditions recommended by ACMG/
ACOG for general population screening.When assessing clin-
ical severity as a criterion for disease inclusion, 14 % felt that
conditions should be limited to those that are lethal in the
neonatal period. The majority (92 %) agreed that conditions
with significant physical and/or mental impairment
should be included in ECS, while 52% agreed that a condition
with any degree of impairment should be included. Eighty-
0% 20% 40% 60% 80% 100%
I am concerned that ECS will lead to decreased societal
tolerance of individuals with genetic conditions
I am concerned that ECS will lead to decreased funding for
treatment/research of rare genetic diseases
If the cost were the same, I woud prefer to be tested for a
larger number of disorders rather than for a smaller number
If I had a 25% risk of having a child with a severe genetic
disease, I would consider pre-implantation genetic diagnosis
(assuming affordable out-of-pocket expense)
If I had a 25% risk of having a child with a severe genetic
disease, I would consider prenatal diagnosis (assuming
affordable out-of-pocket expense)
If I were identified as a carrier for multiple recessive
diseases, I would be more concerned than if I were a carrier
for only one disease
I would rather not know if I were a carrier of a recessive
genetic disease that falls outside of the ACMG/ACOG
guidelines
I would not partake in ECS after conception because it
would increase my anxiety
I would not partake in ECS before conception because it
would increase my anxiety
 GCs' Personal Perspectives on ECS
agree neutral disagree
Fig. 1 GCs’ personal perspectives on ECS
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eight percent stated ECS should include conditions which are
treatable or in which intervention is beneficial. Approximately
11 % of respondents disagreed with including conditions that
have variable phenotypic expressivity. Regarding the state-
ment, BExpanded panels should include any autosomal reces-
sive condition for which accurate testing is available, regard-
less of severity,^ 51 % disagreed and 27 % agreed, with the
remainder being neutral. Forty-nine percent disagreed that
assessing disease prevalence should be used as a criterion
for disease inclusion. The majority (90 %) agreed that condi-
tions assessed with a detection rate of less than 10 % should
not be included in the panel. However, 66 % agreed that a
detection rate of above 50 % is acceptable and almost all
respondents (96 %) stated that a condition with a >80 % de-
tection rate may be included. Refer to Fig. 3 for comprehen-
sive response data.
This survey section contained the only two questions that
revealed statistically different responses between RGCs and
non-RGCs. If not working in the reproductive field, a GC was
more likely to respond that diseases of any severity should be
included in an ECS panel (32 % versus 21 %, p=0.02). Also,
if not working in a reproductive field, a GC was less likely to
agree that there should be a minimum prevalence threshold in
order to include a disease on an ECS panel (22% versus 31%,
p=0.04).
The Role of the Genetic Counselor in the Service Delivery
Model of ECS
Perspectives on the GCs role in criteria for offering ECS, and
the role of GCs in its delivery, were evaluated. Among all
respondents, 92 % stated that pre-test counseling should be
required for all patients prior to having ECS. However, 67 %
agreed that properly trained health professionals other than
GCs could administer pretest counseling, and 31 % stated that
pre-test counseling could be in the form of an information
brochure or video (refer to Fig. 4).
We assessed opinions on the necessary components of in-
formed consent for ECS. Options were to group diseases by
severity, type (e.g., neurological), prevalence, ethnic predilec-
tion, all diseases should be described individually or that ge-
neric consent model was appropriate. Multiple responses
could be chosen. The two most common responses were: a
generic consent model (n=80), or diseases should only be
presented in groups by severity (n=69). This accounts for all
possible responses, including multiple selections (Table 2).
Note that statements on ECS from professional societies,
which assert sufficiency of a generic consent model, were
not yet published at the time of this survey (Edwards et al.
2015; Grody et al. 2013).
We also surveyed participants regarding results scenarios
that merit post-test counseling (Table 3): all results, one part-
ner positive, both partners positive, only by request, or none.
Multiple options could be chosen. The most common re-
sponse was that three scenarios indicate post-test counseling:
when one partner is positive, when both are positive or upon
request (n=148). The secondmost common response was that
all results should be counseled (n=63).
The last set of questions surveyed clinical and non-clinical
factors that influence offering ECS. Nearly half of all GCs
(48 %) agreed that all patients should be offered ECS. We
asked, assuming a 2 week results turnaround time, in which
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100%
I am concerned about the amount of time I will have to spend
following up on results
I am concerned about the amount of time I will have to spend
counseling patients about their ECS results
I foresee ECS being routinely incorporated into clinical
genetics
I am comfortable explaining the genetic information high-
throughput carrier screening technology provides
I feel very knowledgeable about high-throughput carrier
screening technology
 Reproductive GCs' Experiences with ECS
agree neutral disagree
Fig. 2 Reproductive GCs’ experiences with ECS
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0% 20% 40% 60% 80% 100%
have a carrier detection rate of >80%
have a carrier detection rate of 50-79%
have a carrier detection rate of 10-49%
have a carrier detection rate of <10%
have a threshold of prevalence (such at 1/100) in the general
population
have accurate testing available, regardless of severity
have variable phenotypic expressivity
are treatable or where intervention is beneficial
have any degree of mental and/or physical impairment
have significant mental and/or physical impairment
are lethal in the perinatal or pediatric setting
are recommended by ACOG/ACMG
 GCs' Perspectives on ECS Disease Panel Inclusion
agree neutral disagree
Expanded carrier screening panels 
should include diseases that:
Fig. 3 GCs’ perspectives on ECS disease panel inclusion
0% 20% 40% 60% 80% 100%
Informed consent for DNA testing should be implemented
like informed consent for routine medical tests
Genetic information should be treated differently from other
types of medical information
Pre-test counseling for ECS can take the form of an
informational brochure/video
Pre-test counseling for ECS can be administered by an
appropriately trained health professional other than a genetic
counselor
Pre-test counseling for ECS should only be administered by
genetic counselors
Pre-test counseling should be required for all patients
undergoing ECS
 GCs' Perspectives on Pre-test Counseling for ECS
agree neutral disagree
Figure 4 GCs’ perspectives on pre-test counseling for ECS
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clinical circumstances should ECS be offered: 96 % agreed in
the context of consanguinity, 90 % agreed offering pre-
conceptionally, 75 % agreed offering ECS prenatally, 71 %
would offer if there were a family history of a rare recessive
disorder and 77%would offer if there were a family history of
an undiagnosed genetic disease. Refer to Fig. 5 for compre-
hensive response data.
Regarding non-clinical factors that affect likelihood of of-
fering ECS, 30 % of RGCs would only offer ECS if a patient
inquired about the availability of additional genetic testing and
90 % would offer ECS if any patient requests as much infor-
mation as possible. Although ECS panels incur costs relative-
ly similar to those of single-gene carrier screens, we attempted
to assess whether perceived financial status may affect wheth-
er a patient is offered this new technology.When asked wheth-
er they offer all patients identical carrier screening, regardless
of socioeconomic status, 74 % agreed and 14 % did not. A
minority (5 %) stated that they use perceived socioeconomic
status in choosing which testing options to offer. Refer to
Fig. 6 for comprehensive response data.
Discussion
The objective of this study was to assess GCs’ personal and
clinical perspectives on ECS. The survey was administered in
April 2012, approximately 2 years after initial clinical avail-
ability. There has since been substantial growth in utilization
and in recognition: Counsyl’s ECS testing volume has grown
nearly 400 % from April 2012 to March 2015 (unpublished
data) and a comprehensive statement was issued in February
2015 by ACOG, ACMG, NSGC, the Society for Maternal-
Fetal Medicine and the Perinatal Quality Foundation.
Therefore, these data offer a representation of early perspec-
tives and establish a basis for comparison for later surveys.We
plan to re-administer a similar survey, with potential for elab-
oration on some of the questions raised in this study.
Support for Expanded Carrier Screening; Concerns
for Implementation
We found support for expanded carrier screening in this GC
population, including those practicing in reproductive set-
tings. Several questions assessed its desirability or appropri-
ateness and three data points most simply illustrate this sup-
port: 1) only 27 % of all GCs responded that screening panels
should be limited to those diseases currently addressed by
ACMG/ACOG guidelines; 2) given equal cost, 80 % would
personally elect expanded screening; and 3) 92 % expect ECS
to become routine practice. In summary, the group largely
accepted the ECS premise, despite lack of professional society
endorsement, for personal utilization or for current or future
practice.
Cho, et al. (2013) summarized their focus group findings
and found both support and caution regarding ECS. Since
those responses were not quantified, our results are not direct-
ly comparable. In comparison to other health care profes-
sionals, though, our findings are consistent with ECS accep-
tance described in surveys of ACOG and American Society of
Reproductive Medicine audiences (Benn et al. 2014; Ready
et al. 2012).
However, respondents identified questions or concerns
with regard to practical implementation, also consistent with
the same previous studies (Benn et al. 2014; Ready et al.
2012). Half of RGCs stated concern regarding time spent
counseling ECS results or related follow-up testing.
Regarding pre-test informational conveyance, the most com-
mon responses were a generic consent model or to present
diseases according to levels of severity. However, as yet, there
is no consensus on ascribing severity levels to the broad swath
of diseases that can be included on an ECS panel, though a
potential solution has been recently proposed (Lazarin et al.
2014a). A conclusion, though, is that given the many details
that are possible to discuss before testing, the most common
responses focused on simplicity rather than inclusion of all
information. A statement by the ACMG and separate joint
statement by multiple organizations, released after this survey,
propose a generic pre-test approach via informational bro-
chure or video, with genetic counseling available upon request
(Edwards et al. 2015; Grody et al. 2013).
Table 2 Pre-test ECS presentation, most common responses
Presentation element(s) Agreements, n
ECS is sufficiently presented by saying that it
identifies diseases
that can cause a wide range
of complications (generic model).
80
Categorized by severity (e.g., lethal, treatable) 69
Categorized by severity, and
Type (e.g., neurological), and
Prevalence (e.g., most common, very rare),
and Ethnic predilection
43
Categorized by severity, and
Prevalence, and Ethnicity
36
Table 3 Post-test ECS counseling, most common responses
Counseling indication(s) Agreements, n
One partner positive carrier status, or
Both partners positive carrier status, or
On request
217
Always, regardless of results 84
One partner positive carrier status 55
Both partners positive carrier status, or
On request
36
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Insufficient numbers of GCs in the US and elsewhere is a
known limitation – there were approximately four million
pregnancies in the US in 2012 (Martin et al. 2013) and only
1200 GCs that focus on prenatal care (NSGC 2014). With this
in mind, there were seemingly contradictory responses regard-
ing GCs roles in pre-test counseling (which, by definition is
done in larger scale than post-test counseling): 38 % of GCs
responded that pre-test counseling Bshould only be adminis-
tered by GCs,^ but nearly 67 % also agreed it could be ad-
ministered by other health professionals and 31 % responded
that an informational brochure or video was sufficient. The
acceptability of non-formal genetic counseling may depend
on the GCs perception of that professional’s or medium’s ad-
equacy; further study would be illustrative.
Formal post-test genetic counseling for all individual pos-
itive results, as preferred by respondents, also requires sub-
stantial resources when considering that ECS panels can have
individual positive rates of 23 % (Lazarin et al. 2013). ECS by
next-generation sequencing confers even higher positive rates
(Lazarin et al. 2014b). If all pregnant women underwent pre-
test counseling and all positive results underwent post-test
counseling, and a GC is necessary to perform this counseling,
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100%
All patient should be offered expanded carrier screening
Family history of an undiagnosed genetic disease
Family history of a rare recessive disease
Ultrasound abnormality with indication for amniocentesis
Prenatal second trimester counseling
Abnormal nuchal translucency or blood screen counseling
Prenatal first trimester counseling
Preconception counseling
Consanguinity
 Perspectives on Offering ECS in Various Clinical Scenarios
agree neautral disagree
Assuming results take 2 weeks, I feel 
ECSshould be offered in the 
Figure 5 Perspectives on offering ECS in various clinical scenarios
0% 20% 40% 60% 80% 100%
I use my patient's pregnancy status and gestational age as a
factor in determining which carrier screening option I offer
I offer all of my patient's identical carrier screening options
I use my perception of the patient's socioeconomic status in
choosing which test options I offer
I would offer ECS only when the patient specifically inquires
about the availability of additional genetic tests
I would never consider offering ECS to my patients
Reproductive GCs' Perspectives on Other Factors Affecting 
Offering ECS
agree neutral disagree
Figure 6 Reproductive GCs’ perspectives on other factors affecting offering ECS
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1200 GCs would potentially be responsible for 5,000,000
consultations per year (4,000,000 pregnancies+1,000,000
positive carrier results, if all pregnancies were screened).
Interestingly, a majority of obstetricians in the Benn et al.
survey (2014) also responded that GCs should provide genetic
counseling. Meeting the desire for formal genetic counseling,
although it matches each individual patient with the optimal
specialist, suffers from shortage of resources and necessitates
alternative models (Minkoff and Berkowitz 2014) or substan-
tial expansion of the number of RGCs.
The joint statement by Edwards et al. (2015) cites formal
genetic counseling by a board-certified genetic counselor as
indicated only in the case of two individuals identified as
carriers for the same condition. This addresses the smallest
but highest risk population. The joint statement also asserts
that providers should establish a protocol for handling ECS
results. Presumably, this can be done without formal genetic
counseling for most cases, though an optimal and scalable
protocol is yet to be established.
Personal Preferences versus Professional Practices
Two survey sections addressed personal preferences and clin-
ical practice. As previously stated, an overwhelming majority
of GCs preferred to be screened for more diseases rather than
less. In practice, 52 % of RGCs were not offering ECS to any
patients and 40 % were offering it to less than one-third of
patients. This discordance may be based on perspective (for
example, having greater education in genetics may increase
comfort level with obtaining more information), or they may
be based on practical or logistical implementation barriers,
such as availability of counseling time. We also noted that
43 % of RGCs (n=61) agreed that, Ball patients should be
offered ECS.^ Yet, only 6 RGCs responded that they were
actually offering ECS to all patients.
Reasons for discrepancy between what one would make
available to oneself versus one’s patients, and reasons for what
GCs state should be done and what is donemerit further study.
Gestational timing also affected offering rates.
Unsurprisingly, there was a preference for screening at earlier
stages – in rank order, those were preconception, first trimester
and second trimester screening (90, 71 and 43 %,
respectively).
We attempted to assess non-clinical factors that may affect
practice. Availability of time is a concern – over 50 % of
RGCs were concerned about the time necessary to explain
screening results and/or follow up on testing protocols, such
as sequence analysis.
Perceived patient’s SES may be another factor affecting
screening practices for a minority of RGCs. While RGCs re-
ported that they do not use perceived SES in determining
clinical offerings in one question, less agreed with a separate
statement that they offer all patients identical carrier screening
options, regardless of SES. The effect of patients’ real or per-
ceived SES status on counseling protocols, if any, has not been
fully explored and may merit further study.
Differences between GCs in Reproductive Settings
and in Non-reproductive Settings
Differences in offering protocols are, of course, expected be-
tween counselors who see patients for reproductive planning
and those who do not. However, we were interested to deter-
mine any statistically significant differences in opinions. In
general, these were not observed between GCs practicing re-
productive genetics and those in other specialties.
Exceptions to this were found in opinions regarding disease
panel construction. GCs outside of the reproductive field were
more receptive to diseases of any severity level and any prev-
alence. Although we did not assess the reasoning, it may be
that consistent exposure to such diseases (e.g., in pediatric
settings) may influence these opinions.
Practical Implications and Study Limitations
We surveyed approximately 17 % of GCs working in repro-
ductive settings. To our knowledge, this is the first and largest
survey of GCs’ ECS perspectives, practices and knowledge.
Where statistical comparisons were made, they are limited
by increased likelihood of chance findings due to multiple
testing problems inherent with univariate statistical tests.
Statistically significant results should therefore be interpreted
with caution.
The survey covered many areas (a strength) but revealed
the need for in-depth explorations before drawing definitive
conclusions (a limitation). ECS has been rapidly developing -
this survey was administered more than 2 years ago and since
then, the authors observe that ECS has gained acceptance and
utilization among GCs and non-GC healthcare providers.
Therefore, a replication study may find differences in partic-
ular with regard to clinical practice and counseling consider-
ations. For example, the ACMG statement on ECS was not
published at the time of this survey.
GCs perspectives are useful for considering widespread
opinions in the design of practice guidelines that can be based,
in part, on professional opinions. For example, even though a
minimum carrier frequency is often cited as disease inclusion
criterion, less than half of GCs in the present study agreed that
this should persist.
The responses also indicate areas of significant concern for
GCs – in particular, the time and content of pre- and post-test
counseling. These data, and those resulting from further study,
may help to inform alternative models for delivering counsel-
ing, such as involvement by non-GCs, or use of print, video or
Internet media.
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Conclusion and Research Recommendations
We found that in early 2012, approximately 2 years after initial
clinical availability, GCs generally supported ECS, at least in
theory. There were some varying opinions on diseases to be
included, though current ACMG/ACOG guidelines were con-
sidered too restrictive. Informed consent components should
focus on simplicity, including generic consent, and GCs
performing most post-test consultations is desirable, though
this raises questions of resource availability. We also found
that although there were acceptance and strong personal inter-
est in testing, actual clinical utilization was lagging. Since
administration of the survey, ECS utilization has increased
and statements from professional organizations have been is-
sued. The authors plan to resurvey for comparison, which may
reveal different findings, particularly in regard to utilization,
and indicate changing dynamics in the GC profession.
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